Lantheus Holdings, Inc. (NASDAQ:LNTH) Director David F. Burgstahler sold 102,958 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $16.56, for a total value of $1,704,984.48. Following the sale, the director now owns 13,248 shares of the company’s stock, valued at $219,386.88. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Lantheus Holdings, Inc. (NASDAQ LNTH) opened at 16.75 on Tuesday. The company’s 50 day moving average price is $17.42 and its 200-day moving average price is $15.26. The stock has a market capitalization of $625.61 million, a PE ratio of 22.88 and a beta of 0.94. Lantheus Holdings, Inc. has a 52 week low of $7.18 and a 52 week high of $20.45.
Lantheus Holdings (NASDAQ:LNTH) last released its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.18. The firm had revenue of $88.83 million during the quarter, compared to analyst estimates of $80.56 million. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. Lantheus Holdings’s revenue was up 13.9% compared to the same quarter last year. During the same period last year, the business posted $0.24 earnings per share. Equities research analysts predict that Lantheus Holdings, Inc. will post $1.12 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/09/12/lantheus-holdings-inc-lnth-director-david-f-burgstahler-sells-102958-shares.html.
LNTH has been the subject of a number of analyst reports. Credit Suisse Group upped their price objective on Lantheus Holdings from $14.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC restated a “buy” rating and set a $22.00 price objective (up from $18.00) on shares of Lantheus Holdings in a research note on Wednesday, August 2nd. Cantor Fitzgerald initiated coverage on Lantheus Holdings in a research note on Monday, July 17th. They set an “overweight” rating and a $22.00 price objective for the company. Zacks Investment Research cut Lantheus Holdings from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Finally, BidaskClub cut Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 17th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $18.60.
A number of large investors have recently added to or reduced their stakes in LNTH. State of Alaska Department of Revenue purchased a new stake in Lantheus Holdings during the 2nd quarter worth about $102,000. Municipal Employees Retirement System of Michigan purchased a new stake in Lantheus Holdings during the 2nd quarter worth about $107,000. LS Investment Advisors LLC purchased a new stake in Lantheus Holdings during the 2nd quarter worth about $112,000. Quantbot Technologies LP purchased a new stake in Lantheus Holdings during the 2nd quarter worth about $117,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in Lantheus Holdings during the 2nd quarter worth about $141,000. Hedge funds and other institutional investors own 84.35% of the company’s stock.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.